|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Yescarta
gptkb:Immunomedics
Kite Pharma
Pharmacyclics
|
|
gptkbp:CEO
|
gptkb:Daniel_O'Day
|
|
gptkbp:clinicalTrials
|
gptkb:COVID-19
Cancer
HIV
Hepatitis C
|
|
gptkbp:focus
|
antiviral drugs
|
|
gptkbp:founded
|
1987
|
|
gptkbp:founder
|
gptkb:Michael_L._Riordan
|
|
gptkbp:headCoach
|
over 12,000 employees
|
|
gptkbp:headquarters
|
gptkb:Foster_City,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Gilead
|
|
gptkbp:notableFeature
|
gptkb:Atripla
gptkb:Sovaldi
gptkb:Truvada
Biktarvy
Remdesivir
Harvoni
|
|
gptkbp:partnerships
|
gptkb:Galapagos_NV
gptkb:GSK
gptkb:AstraZeneca
gptkb:TetraLogic_Pharmaceuticals
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:philanthropy
|
gptkb:Gilead_Foundation
Gilead's_COVID-19_response
Gilead's_cancer_research_funding
Gilead's_hepatitis_C_initiatives
Gilead's_HIV/AIDS_programs
|
|
gptkbp:revenue
|
$24.4 billion (2020)
|
|
gptkbp:stockExchange
|
gptkb:GILD
|
|
gptkbp:subsidiary
|
gptkb:Gilead_Sciences_Singapore_Pte._Ltd.
gptkb:Gilead_Sciences_S.A.
gptkb:Yescarta
gptkb:Immunomedics
gptkb:Gilead_Sciences_Ireland_UC
gptkb:Gilead_Sciences_Canada,_Inc.
gptkb:Gilead_Sciences_GmbH
gptkb:Gilead_Sciences_Australia_Pty_Ltd.
Kite Pharma
Pharmacyclics
|
|
gptkbp:website
|
www.gilead.com
|